Translating biology to clinical studies in pediatric oncology
VAGABOND consortium
“VAGABOND Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students” aims to create a multidisciplinary and multi-sectoral program to validate new therapeutic interventions in paediatric cancer. The program is funded by the European Commission under the Horizon 2020 programme (Marie Sklodowska-Curie Actions Innovative Training Network) and offers 15 fully funded PhD positions. The consortium is coordinated by the Princess Máxima Center for Pediatric Oncology and consists of 12 academic and 6 non-academic partners from 8 European countries.
15 PhD projects
The research projects are focused on genetic, epigenetic and immunological targets and hosted by 11 academic and non-academic institutes located in 8 European Countries.
Our goal
The overall goal of VAGABOND is to create an efficient approach to validate new target-drug combinations in paediatric cancer. VAGABOND will gain knowledge in 8 difficult to treat paediatric cancers to overcome the limitation of their rare nature by efficient knowledge and data-sharing between beneficiaries and partners. VAGABOND will exchange expertise in the 4 steps of the proof of concept pipeline for pre-clinical drug development of genetic, epigenetic and immunologic targets. VAGABOND will train a new generation of young scientist to translate science to therapeutic applications fuelling innovation and entrepreneurship.
PhD positions
The PhD students will get equipped with all necessary qualities and skills to make a significant difference in pre-clinical drug development. They will get the opportunity to work with and gain experience from world-class scientist from leading European industrial partners and academic institutes in the area of pediatric oncology. Read more about the individual research projects here.